ANTIBODY-MEDIATED REJECTION OF THE KIDNEY AFTER SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION (SPKT): ALEMTUZUMAB IS NOT SUPERIOR TO BASILIXIMAB AS INDUCTION TREATMENT: 88